CureVac COVID-19 Vaccine 2023
CureVac COVID-19 vaccine candidates are based on an advanced second-generation messenger ribonucleic acid (mRNA) backbone. CureVac's proprietary technology principle is mRNA as a data carrier instructing the human body to produce proteins capable of fighting various diseases. This innovative mRNA technology instructs the human body to activate its defense mechanism. It uses the natural messenger substance mRNA that contains the construction manual needed to produce proteins. This messenger substance is programmed with information about one coronavirus protein and injected into the human body. The mRNA is also encapsulated in a protective shell to prevent the mRNA's degradation and improve vaccine effectiveness.
CureVac's RNAoptimizer platform aims to optimize mRNA medicines' properties based on its three core pillars: protein design, optimization, and delivery. CureVac's technology can also be adapted to avoid immune activation for protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from various diseases. The different parts of a CureVac-customized mRNA molecule create a packaged product specially optimized for various multiples.
On August 1, 2023, CureVac announced the dosing of the first participant in a Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in collaboration with GSK. The Phase 2 study will evaluate the safety, reactogenicity, and immune responses of single booster doses of two modified mRNA COVID-19 vaccine candidates. The monovalent candidate, CV0601, encodes the spike protein of the omicron BA.4-5 variant. In line with the current standard of care, the bivalent candidate, CV0701, encodes the spike protein of both the omicron BA.4-5 variant and the original SARS-CoV-2 virus. The study is active-controlled, including a licensed bivalent COVID-19 comparator vaccine. An initial data readout of the study is expected early in the first half of 2024.
The CureVac-GSK COVID-19 collaboration was announced in February 2021.
CureVac N.V. (Nasdaq: CVAC) is a global biopharmaceutical company in mRNA technology with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. It is headquartered in Tübingen, Germany, and employs more than 900 people in Tübingen, Frankfurt, and Boston, USA. Officially founded in 2000, CureVac is the world's first company to harness mRNA for medical purposes successfully. Further information can be found at www.curevac.com.
CureVac Flu Vaccine Combination
On January 31, 2023, the Company announced positive extended preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu conducted in collaboration with GSK. The newly reported data focus on older adult age groups in both indications. Detailed data can be reviewed in the associated presentation. The data further support the decision to advance updated versions of the modified mRNA COVID-19 and flu vaccine constructs to the next stage of clinical testing in 2023.
CureVac Vaccine News For 2020 - 2023
August 17, 2023 - CureVac announced it continues to advance its broad clinical development program in prophylactic vaccines in collaboration with GSK.
April 25, 2023 - "Last year was transformative for CureVac, as we have made significant strides in advancing our unique end-to-end mRNA capabilities," said Alexander Zehnder, Chief Executive Officer at CureVac. "We have successfully executed clinical programs in COVID-19 and flu as demonstrated by positive preliminary data reported in early 2023, validating our differentiated mRNA technology platform.
January 30, 2023 - "The exciting preliminary data seen among older adults for our COVID-19 and flu programs significantly add to the validation of our technology platform into this highly relevant and at-risk population," said Franz-Werner Haas, CEO of CureVac. "The strong immune responses we observed in both indications further support our commitment to advancing to the next stage of product development in 2023."
June 18, 2021 - The journal Nature published an article: CureVac COVID vaccine let-down spotlights mRNA design challenges.
February 3, 2021 - Germany-based CureVac N.V. announced a new €150m collaboration with GSK, building on their existing relationship to develop next-generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.
June 17, 2020 - CureVac to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate.
May 14, 2020 - CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, announced positive preclinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).
Vaccine Clinical Trials
CureVac AG COVID-19 mRNA vaccine candidate tests the immunogenicity, safety, and efficacy in clinical trials.